Global, inspection-credible compliance
for medical device organizations.
Global Scrutiny, One Coherent Compliance System
Medical device regulators, notified bodies, and audit organizations assess systems, not documents. They test whether design controls, ISO 14971 risk management, supplier controls, and post-market surveillance operate as a single, traceable operating discipline across jurisdictions. PHALANX8 anchors that discipline in ISO 13485 and ISO 14971, then aligns it to the oversight regimes that dominate global device operations, including FDA QMSR, EU MDR and IVDR, UK medical device requirements, and MDSAP markets.
The objective is defensibility at speed. DHF, risk files, technical documentation, supplier records, complaints, and CAPA remain coherent as products evolve and markets expand. Governance cadence makes gaps visible early, before they become inspection findings or regulatory delays.
Where Global Device Programs Lose Control
Global scale turns medical device compliance into a coherence problem. Each added market introduces new audit touchpoints, documentation expectations, and decision timelines. Many organizations respond by layering local additions on top of the core QMS. Over time, the system becomes harder to operate, not because requirements are unclear, but because evidence and ownership drift across regions and functions.
The fracture pattern is consistent. Design changes outpace DHF maintenance. Risk files lag design decisions. Supplier changes move outside validated corridors. Software release cadence strains change control and verification discipline. Post-market signals accumulate without clean translation into CAPA with clear closure criteria. The result is predictable: rework, slower decisions, and readiness that depends on heroics rather than a steady operating rhythm.
One ISO-anchored System, Aligned Across Jurisdictions
Global scale works when the organization runs a single quality and risk system, not different interpretations across markets. PHALANX8 anchors execution in ISO 13485 for the QMS and ISO 14971 for lifecycle risk management, so design controls, verification and validation, supplier governance, change control, post-market surveillance, and CAPA remain traceable as a single operating discipline.
From that foundation, PHALANX8 maps the jurisdiction overlays without duplicating the system. That includes FDA’s QMSR, enforceable February 2, 2026, EU MDR (EU) 2017/745, IVDR (EU) 2017/746, UK MDR 2002 (as amended), and MDSAP, which enables a single audit model across participating regulatory authorities.
Where software or clinical evidence is material to approval and surveillance, PHALANX8 aligns delivery to IEC 62304 software lifecycle expectations and ISO 14155 good clinical practice for device clinical investigations.
How PHALANX8 Engages
PHALANX8 strengthens global medical device compliance by turning requirements into operating control. Engagements are structured around coherence: clear standards, clear ownership, and clear evidence that design, quality, supplier, and post-market decisions remain defensible under scrutiny across jurisdictions.
Work starts by establishing a single backbone, then mapping it cleanly to the markets in scope. ISO 13485 and ISO 14971 anchor the system discipline. Jurisdictional overlays such as FDA QMSR, EU MDR and IVDR, UK requirements, and MDSAP expectations are translated into practical execution so teams understand not only what is required, but how compliance is evaluated in practice. From there, PHALANX8 stabilizes the evidence chain across DHF, risk files, verification and validation, supplier controls, complaints, and CAPA so intent connects to outcome without gaps.
The approach is deliberately pragmatic. Effort concentrates where risk accumulates and where intervention materially improves readiness, resilience, and credibility, especially in high-velocity areas such as design change, software release cadence, supplier drift, and post-market signal management. The objective is sustained defensibility without slowing product progress as portfolios expand and global oversight intensifies.
Moving Forward
PHALANX8 supports medical device organizations operating across jurisdictions as portfolios expand, oversight intensifies, and timelines compress. For teams facing a near-term FDA inspection, notified-body review under EU MDR or IVDR, QMSR transition pressure, an MDSAP audit cycle, or a high-velocity design or software change, the first step is a focused discussion to align on scope, pressure points, and what “defensible” looks like in day-to-day execution.
Review the focus areas to see where support is most often needed across QMS, design controls, risk management, supplier oversight, and post-market surveillance, or use the Get In Touch button below to start a conversation.
